Atrial fibrillation ablation – Your questions answered: Part 2

   Rated 5 / 5 stars

Save

CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0.5 mins

Educational Activities (EA)
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 mins

Reviewing Performance (RP)
These are activities that require reflection on feedback about your work.

MO
0 mins

Measuring Outcomes (MO)
These are activities that use your work data to ensure quality results.

Listen to the episode

Description

In this episode:

  • Oral antiarrhythmics have limited efficacy and significant risks
  • Catheter ablation is now a first-line option in suitable patients
  • Newer ablation technology – Pulsed field ablation (PFA) is safer and faster
  • Anticoagulation decisions remain based on stroke risk, not ablation status
  • Genuine post-procedural issues may be benign
  • Ongoing healthcare professional role – Blood pressure and risk factor control

 

The questions answered in this podcast are listed below.
They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars.

  1. How effective are oral antiarrhythmic medications?
  2. Does this cure atrial fibrillation?
  3. What is the current state of ablation technology?
  4. Can you explain what you mean by “rapid” and provide an example of how long a procedure typically takes?
  5. Does reduced scarring decrease the likelihood or complexity of needing a repeat ablation?
  6. What are some of the contraindications in terms of structurally abnormal heart that would be contraindications for the patient?
  7. How should atrial fibrillation be approached in patients with severe ischaemic heart disease? Does this complicate treatment?
  8. If a patient has an AF ablation, can they come off my anticoagulant?
  9. How do you manage patient’s embolic issues?
  10. How soon after the procedure can patients typically be discharged?
  11. Following successful AF suppression, is it possible for patients to stop taking DOACs or other anticoagulants?
  12. After discharge, how soon should patients follow up with their GP?
  13. What should the GP monitor and what should be communicated back to the specialist?
  14. When will you consider AV node ablation and insertion of a pacemaker?

 

Expert: Prof Rukshen Weerasooriya, Cardiac Electrophysiologist

Host: Dr David Lim, GP and Medical Educator

Total time: 44 mins

 

Recommended resources:

 

Last Updated: 1 Jul, 2025

Rate this podcast
Help your colleagues find podcasts they'll enjoy by rating this podcast out of five stars.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Andrew Leech

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Brendon Yee

Prof Brendon Yee

OSA – Which Test for Which Patient

Dr Sonia Davison

Dr Sonia Davison

Musculoskeletal Health in Menopause

Mr David Gardner

Mr David Gardner

AHPRA-Proof Your Practice – Social Media Risks for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Rukshen Weerasooriya

expert

Prof Rukshen Weerasooriya

Sub-specialist Cardiac Electrophysiologist; Hollywood Private Hospital, Founder, CloudHolter

Recent articles

Find your area of interest

Share this

You have completed the Educational Activities (EA) component of this activity.

Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.

You will be taken to explore further CPD learning available to you.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease